{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-021283","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.394378+00:00","generated_at":"2026-05-16T12:05:48.728428+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tonix Pharmaceuticals prices $20M registered direct offering with Point72; shares and pre-funded warrants","bullets":["Sold 615,025 shares at $16.26 and pre-funded warrants for 615,025 shares at $16.259 to Point72; gross proceeds ~$20M.","Closing expected Dec 30, 2025; TD Cowen sole placement agent.","Net proceeds to fund commercialization, pipeline development, and working capital.","30-day lock-up on additional equity issuance; 180-day ban on variable rate transactions.","Directors and officers also subject to 30-day lock-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-021283","json":"https://secwatch.observer/filing/0001999371-25-021283.json","markdown":"https://secwatch.observer/filing/0001999371-25-021283.md","text":"https://secwatch.observer/filing/0001999371-25-021283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125021283/0001999371-25-021283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125021283/tonix-8k_122925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:05:48.728428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08763cc86a082dadc4f8451ba1cdddd432ff6892","claim":"Tonix Pharmaceuticals Holding Corp. entered into Placement Agency Agreement with TD Securities (USA) LLC valued at 6.0% cash placement fee on gross proceeds; expense reimbursement up to $100,000 (effective 2025-12-29).","evidence_excerpt":"On December 29, 2025, the Company entered into a placement agency agreement (the \"Placement Agency Agreement\") with TD Securities (USA) LLC (the \"Placement Agent\"), pursuant to which the Placement Agent was engaged as the placement agent for the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125021283/0001999371-25-021283-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"TD Securities (USA) LLC"},{"label":"Value","value":"6.0% cash placement fee on gross proceeds; expense reimbursement up to $100,000"},{"label":"Effective","value":"2025-12-29"}],"fact_type":"material_agreement"},{"claim_id":"bc0aebeb1b544cb5009d175a9e8752f4f93554d2","claim":"Tonix Pharmaceuticals Holding Corp. entered into Securities Purchase Agreement with a single institutional investor valued at $20.0 million gross proceeds; offering price per Share $16.26, per Pre-Funded Warrant $16.259 (effective 2025-12-29).","evidence_excerpt":"On December 29, 2025, Tonix Pharmaceuticals Holding Corp. (the \"Company\") entered into a securities purchase agreement (the \"Purchase Agreement\") with a single institutional investor (the \"Purchaser\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125021283/0001999371-25-021283-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a single institutional investor"},{"label":"Value","value":"$20.0 million gross proceeds; offering price per Share $16.26, per Pre-Funded Warrant $16.259"},{"label":"Effective","value":"2025-12-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}